InvestorsHub Logo
Followers 39
Posts 9514
Boards Moderated 0
Alias Born 05/12/2006

Re: None

Saturday, 04/15/2017 9:01:35 PM

Saturday, April 15, 2017 9:01:35 PM

Post# of 222
Aptevo will be speaking on May 24, at the antibody congress.

12:01

ADAPTIR™ BISPECIFICS, A NOVEL PLATFORM FOR DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS

Key features and differentiating aspects of the ADAPTIR™ bispecific platform, including new preclinical in vivo and in vitro activity, pharmacokinetic and manufacturability data.  ADAPTIR™ bispecific proteins offer advantages over other formats, derived from the flexible and modular nature of the ADAPTIR™ structure. Potent biological activity can be achieved, while retaining traditional antibody-like manufacturing characteristics. One ADAPTIR™ molecule is currently undergoing clinical trials, with several more bispecific immunotherapies in preclinical development.

Mr David Bienvenue, Director of Protein Sciences, Aptevo Therapeutics

- See more at: http://www.terrapinn.com/conference/americas-antibody-congress/Agenda-Day-2.stm#sthash.ySCX3fN9.dpuf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APVO News